Publications by authors named "Eve Leconte"

Claim this Profile
A
A stratified adaptive two-stage design with co-primary endpoints for phase II clinical oncology trials.
Bastien Cabarrou, Eve Leconte, Patrick Sfumato, Jean-Marie Boher, Thomas Filleron

BMC Med Res Methodol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Variable Selection Methods for Time-to-Event Data in High-Dimensional Settings.
Julia Gilhodes, Florence Dalenc, Jocelyn Gal, Christophe Zemmour, Eve Leconte

Comput Math Methods Med· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addressing heterogeneity in the design of phase II clinical trials in geriatric oncology.
Bastien Cabarrou, Patrick Sfumato, Loïc Mourey, Eve Leconte, Laurent Balardy

Eur J Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Focus on an infrequently used quantity in the context of competing risks: The conditional probability function.
Bastien Cabarrou, Florence Dalenc, Eve Leconte, Jean-Marie Boher, Thomas Filleron

Comput Biol Med· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of variable selection methods for high-dimensional survival data with competing events.
Julia Gilhodes, Christophe Zemmour, Soufiane Ajana, Alejandra Martinez, Jean-Pierre Delord, Eve Leconte

Comput Biol Med· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Statistical Approach to Determine the Optimal Duration of Post-Treatment Follow-Up: Application to Metastatic Nonseminomatous Germ Cell Tumors.
Serge M A Somda, Stéphane Culine, Christine Chevreau, Karim Fizazi, Eve Leconte

Clin Genitourin Cancer· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal scheduling of post-therapeutic follow-up of patients treated for cancer for early detection of relapses.
Serge Ma Somda, Eve Leconte, Jean-Marie Boher, Bernard Asselain, Andrew Kramar

Stat Methods Med Res· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncologic surveillance after curative treatment: A probability-based approach should be preferred to a risk-based approach.
Serge M A Somda, Dalenc Florence, Eve Leconte, Thomas Filleron

Urol Oncol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determining the length of posttherapeutic follow-up for cancer patients using competing risks modeling.
Serge M A Somda, Eve Leconte, Andrew Kramar, Nicolas Penel, Christine Chevreau

Med Decis Making· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smooth conditional distribution function and quantiles under random censorship.
Eve Leconte, Sandrine Poiraud-Casanova, Christine Thomas-Agnan

Lifetime Data Anal· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis